Prepared for Michael B. | Delivered December 16, 2019
Review your project details
To gain a better understanding of the oncology market including the major players, market size and projected growth.
The market size of the oncology drug market in 2018 was
The estimated CAGR through 2026 is estimated at
of growth include increasing levels of drug approval, emergence of biosimilar drugs, and increasing healthcare costs fueling the need for research and development into new drug alternatives.
Mergers and acquisitions
within the oncology market has been a growing trend over the last several years.
There have been over
400 mergers and acquisitions
between companies "in the gene therapy, immuno-oncology, microbiome and orphan drugs therapeutic space" in North American since 2014.
Globally since 2014, there have been
in this space.
Top 10 Oncology Companies
top 10 oncology
drug companies based off of oncology department revenue are:
Roche Holding AG: $25.659 billion.
Celgene Corporation : $13.657 billion
Novartis AG : $11.811 billion
Bristol-Myers Squibb Company : $10.312 billion
Johnson & Johnson : $9.844 billion
Merck & Co., Inc. : $8.243 billion
Pfizer Inc. : $7.202 billion
AstraZeneca PLC : $6.028 billion
Eli Lilly : $4.260 billion
AbbVie Inc. : $3.934 billion
Roche is one of the largest biopharmaceutical companies in the world with
in oncology, nueroscience, infectious disease, immunology, cardiovascular, ophthalmology, haemophilia, and respiratory.
In terms of oncology,
is on breast cancer, bladder cancer, cervical cancer, colorectal cancer, lung cancer, haematology, liver cancer, skin cancer, ovarian cancer, and renal cell carcinoma.
In August 2019, the FDA approved Roche's
for use in patients with "ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours."
Drugs expected to be submitted
for approval by Roche in 2020 include Idasanutlin, Kadcyla, Pertuzumab, Cotellic, Ipatasertib, and Tecentriq.
Roche believes in partnering with other companies and scientists to expand research into oncology therapies. Some
include BioNTech, Adaptive Biotechnologies, and Tusk Therapeutics.